Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

News | Structural Heart

January 6, 2021 — The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F ...

Home January 06, 2021
Home
The most popular DAIC content in December 2020 included the Boston Scientific Lotus TAVR valve being taken off the market, CMS approving expanding coverage of LVADs for more Medicare patients and numerous COVID-19 related cardiology stories and videos.
Feature

January 5, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home January 05, 2021
Home
News | Structural Heart

December 29, 2020 — Edwards Lifesciences announced Dec. 21 that the first patient was treated in the RESTORE clinical ...

Home December 29, 2020
Home
News | Structural Heart

December 29, 2020 — Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ultra ...

Home December 29, 2020
Home
COVID-19 related topics by far out-paced all other topics in cardiology in 2020 on the DAIC website. Several stories topped the list related to the cardiovascular issues with hydroxychloroquine being used as a treatment for the virus. Top new device technologies in 2020 included European approval of the Abbott Tendyne transcatheter mitral valve, FDA approval of Medtronic's new Micra AV pill-sized pacemaker, and FDA clearance of the first drug-eluting stent with short-duration dual-antiplatelet therapy.
Feature | Dave Fornell, Editor

Here are the top 25 best performing articles on the Diagnostic and Interventional Cardiology (DAIC) website from 2020 ...

Home December 28, 2020
Home
This year's top videos are dominated by COVID-19's impact on cardiology and many of the videos from a series produced this year on Tuft Medical Center's cardiology program. Top DAIC cardiology videos from 2020 #TuftsmedicalCenter #Tufts #COVID19
Feature | Dave Fornell, Editor

Here are the top performing 25 videos on the DAIC website in 2020. The picks are based on Google Analytics of the DAIC ...

Home December 23, 2020
Home
News | Heart Valve Technology

December 14, 2020 - Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an ...

Home December 14, 2020
Home
COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC
Feature | Cardiovascular Business | Dave Fornell, Editor

December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home December 01, 2020
Home
News | Hemodynamic Monitoring Systems

December 1, 2020 — A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve ...

Home December 01, 2020
Home
Feature | Heart Valve Technology

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

Home November 17, 2020
Home
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | Dave Fornell, Editor

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

Home November 17, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
News | Atrial Fibrillation

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

Home October 29, 2020
Home
Subscribe Now